-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74

Benzinga·08/21/2026 12:48:18
语音播报
Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $67 to $74.